Cargando…

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein

P-glycoprotein (P-gp) pumps multiple types of drugs out of the cell, using energy generated from ATP, and confers multidrug resistance (MDR) on cancer cells. ZD6474 is an orally active, selective inhibitor of the vascular endothelial growth factor receptor, epidermal growth factor receptor, and rear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mi, Y, Lou, L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360411/ https://www.ncbi.nlm.nih.gov/pubmed/17912240 http://dx.doi.org/10.1038/sj.bjc.6603985

Ejemplares similares

Reply: ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
por: Zheng, Li-sheng, et al.
Publicado: (2009)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
por: Gyémánt, N, et al.
Publicado: (2010)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010)

Irradiation of rat brain reduces P-glycoprotein expression and function
por: Bart, J, et al.
Publicado: (2007)

ZD6474 in combination with paclitaxel and UVB irradiation enhances the antiproliferative effect and apoptosis on breast carcinoma
por: Sarkar, S, et al.
Publicado: (2009)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
por: Liu, Jiani, et al.
Publicado: (2015)

Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells
por: Adigbli, D K, et al.
Publicado: (2007)

Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells
por: Lucia, M B, et al.
Publicado: (2011)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
por: Meyerhardt, Jeffrey A., et al.
Publicado: (2012)

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines
por: Kostrzewa-Nowak, D, et al.
Publicado: (2005)

Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells
por: Martín, V, et al.
Publicado: (2013)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2011)

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer
por: McCarty, M F, et al.
Publicado: (2004)

The role of glucocorticoids in the induction of zinc-α(2)-glycoprotein expression in adipose tissue in cancer cachexia
por: Russell, S T, et al.
Publicado: (2005)

ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway
por: Liu, Wenting, et al.
Publicado: (2022)

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
por: Fanciullino, R, et al.
Publicado: (2007)

Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects
por: Liu, T, et al.
Publicado: (2013)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
por: Sarkar, Siddik, et al.
Publicado: (2013)

Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells
por: Li, Ling, et al.
Publicado: (2018)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5lm2kq5v21o6gbkjqo7d0j3p58